Mouse Lung Fibroblast Resistance to Fas-Mediated Apoptosis Is Dependent on the Baculoviral Inhibitor of Apoptosis Protein 4 and the Cellular FLICE-Inhibitory Protein
Overview
Affiliations
A characteristic feature of idiopathic pulmonary fibrosis (IPF) is accumulation of apoptotic resistant fibroblasts/myofibroblasts in the fibroblastic foci. As caveolin (Cav)-null mice develop pulmonary fibrosis (PF), we hypothesized that the participating fibroblasts display an apoptosis-resistant phenotype. To test this hypothesis and identify the molecular mechanisms involved we isolated lung fibroblasts from Cav-null mice and examined the expression of several inhibitors of apoptosis (IAPs), of c-FLIP, of Bcl-2 proteins and of the death receptor CD95/Fas. We found significant increase in XIAP and c-FLIP constitutive protein expression with no alteration of Bcl-2 and lower levels of CD95/Fas. The isolated fibroblasts were then treated with the CD95/Fas ligand (FasL) to induce apoptosis. While the morphological and biochemical alterations induced by FasL were similar in wild-type (wt) and Cav-null mouse lung fibroblasts, the time course and the extent of the alterations were greater in the Cav-null fibroblasts. Several salient features of Cav-null fibroblasts response such as loss of membrane potential, fragmentation of the mitochondrial continuum concurrent with caspase-8 activation, and subsequent Bid cleavage, prior to caspase-3 activation were detected. Furthermore, M30 antigen formation, phosphatidylserine expression and DNA fragmentation were caspase-3 dependent. SiRNA-mediated silencing of XIAP and c-FLIP, individually or combined, enhanced the sensitivity of lung fibroblasts to FasL-induced apoptosis. Pharmacological inhibition of Bcl-2 had no effect. Together our findings support a mechanism in which CD95/Fas engagement activates caspase-8, inducing mitochondrial apoptosis through Bid cleavage. XIAP and c-FLIP fine tune this process in a cell-type specific manner.
Cellular and Molecular Mechanisms in Idiopathic Pulmonary Fibrosis.
Zhang Y, Wang J Adv Respir Med. 2023; 91(1):26-48.
PMID: 36825939 PMC: 9952569. DOI: 10.3390/arm91010005.
Targeting Histone Deacetylases in Idiopathic Pulmonary Fibrosis: A Future Therapeutic Option.
Korfei M, Mahavadi P, Guenther A Cells. 2022; 11(10).
PMID: 35626663 PMC: 9139813. DOI: 10.3390/cells11101626.
Mizikova I, Lesage F, Cyr-Depauw C, Cook D, Hurskainen M, Hanninen S Stem Cells. 2022; 40(5):479-492.
PMID: 35445270 PMC: 9199848. DOI: 10.1093/stmcls/sxab023.
Identification and Validation of Aging-Related Genes in Idiopathic Pulmonary Fibrosis.
He J, Li X Front Genet. 2022; 13:780010.
PMID: 35211155 PMC: 8863089. DOI: 10.3389/fgene.2022.780010.
Ali F, Mohammed H, Elroby Ali D Cell Stress Chaperones. 2021; 27(1):55-70.
PMID: 34881408 PMC: 8821758. DOI: 10.1007/s12192-021-01248-8.